EphA2 and EphA3 Maintain Tumour Initiating Cells and are Therapeutic Targets in Brain Cancer

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1078893

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

High-grade glioma (HGG) is the most common adult brain cancer; current treatments have increased survival times by months only. Our studies have shown brain cancer specific expression of a family of cell surface proteins called Eph receptors. Furthermore we have shown targeting these receptors with Eph antibodies leads to a significant reduction in brain cancer tumour growth. We now propose to test targeting these receptors in combination to achieve greater responses with minimal side effects.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $612,860.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Molecular Targets

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Eph receptors | glioblastoma | glioma | microenvironment | therapeutic antibodies

Related Links